DAIKI

Daiki is an artificial intelligence company with offices in Vienna and the USA. It was founded in 2023 as a spin-off of a research project about ethical AI between the University of Vienna and Gradient Zero, a machine learning company based in Vienna. Our multidisciplinary team combines legal, ethical, design, and machine learning expertise. Daiki’s SaaS platform combines AI strategy and governance to help teams 'get AI done'; we enable organizations to successfully implement AI projects while meeting industry-specific, local, and international compliance requirements.

Daiki, founded as a research project spinoff between the University of Vienna and Gradient Zero, provides SaaS solutions for AI governance and compliance with the EU AI Act and ISO standards.

Empowering Tomorrow's Innovations with Generative AI Infrastructure

Generative AI Infrastructure

Daiki is an AI governance and compliance solutions provider that offers a SaaS platform, which integrates document and quality management systems (eQMS) with streamlined processes for AI development. It helps organizations comply with the EU AI Act and ISO standards, including ISO 13485 for medical device manufacturers.&nbsp;

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

DAIKI Raises €1.5 Million in Seed Round

Daiki, founded as a research project spinoff between the University of Vienna and Gradient Zero, provides SaaS solutions for AI governance and compliance with the EU AI Act and ISO standards.Daiki provides AI model oversight and EU AI Act compliance through its patent-pending AI Registry, compatible with C2PA. Its infrastructure supports efficient AI implementation across stages, including problem definition, data preprocessing, model development, testing, and model maintenance. Daiki’s tech stack includes secure private LLMs and a retrieval-augmented generation (RAG) system.&nbsp;The platform offered integrations with multiple platforms, including Jira, Microsoft Azure, and Amazon SageMaker. (October 2024).&nbsp;Key clients and partnershipsThe company caters to firms in the healthcare and manufacturing sectors, focused in Austria, Germany, the UK, the Netherlands, Scandinavia, and Switzerland. Notable clients included University Hospital Basel, Seco Tools, and Nagene.

<div>
 
 Founded in Israel, NeuReality specializes in providing hardware infrastructure to streamline computation processes to accelerate the development of AI applications. Its technology assists AI inferencing deployment by offering a comprehensive system solution that seamlessly supports a vast array of deep learning models.
 
 
 NeuRealitys&rsquo; infrastructure includes an architecture called the Network Addressable Processing Unit (NAPU) to maximize the capabilities of Deep Learning Accelerators (DLAs). This design facilitates inference through purpose-built NAPUs that are specifically crafted for AI inference tasks, enhancing performance and efficiency.
 
 
 The NR1 AI Inference Solution by NeuReality is a comprehensive system comprising architecture, hardware, and software platforms. Launched in November 2023, it intends to simplify the installation, utilization, and management of AI, making it accessible and manageable for users.
 
 
 The hardware offerings of the solution include,
 
 
 1. 
 NR1 Network Addressable Processing Unit
 : A network addressable inference Server-on-a-Chip with an embedded Neural Network Engine, which is a workflow-optimized hardware device with specialized processing units, native network capabilities, and virtualization capabilities
 
 
 2. 
 NR1-M&trade; AI Inference Module
 : A full-height, double-wide PCIe card containing one NR1 Network Addressable Processing Unit (NAPU) system-on-chip and a network addressable Inference Server that can connect to an external Deep Learning Accelerator (DLA)
 
 
 3. 
 NR1-S AI Inference Appliance
 : An optimized design for an inference server that contains NR1-M modules with the NR1 NAPU, which enables disaggregated AI service in a scalable and efficient architecture
 
 
 The software component of the solution is designed to be compatible with any trained model from any development environment. It includes tools that handle the entire AI pipeline and enable seamless connection of AI workflows to any environment.
 
 
 NeuReality differs from traditional AI chip connectivity in replacing CPU-centric support with an AI-centric platform. This allows components to communicate directly with AI accelerators, eliminating the need for commands to pass through a central processing unit. Additionally, the technology enables AI accelerators to connect with each other, enhancing efficiency and performance in AI applications. It also claims its AI-centric approach reduces complexity, cost, and power usage. The firm claims it can reduce inference costs by 90%.
 
 
 Key customers and partnerships
 
 
 In November 2021, NeuReality teamed up with IBM to develop advanced AI inference technology by enhancing its NR1 chip and system for use in IBM's Hybrid Cloud.
 
 
 In September 2021, the company partnered with Xilinx to develop AI-centric platforms that improve real-world AI applications. This collaboration was intended to focus on NeuReality's AI-centric inference platform NR1-P and address existing issues with AI deployment including cost and complexity.
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27745">
 March 2024
 </a>
 , NeuReality secured USD 20 million in funding led by The European Innovation Council (EIC) Fund. The funds were intended to accelerate the deployment of NeuReality&rsquo;s NR1AI Inference Solution.
 
 
 In December 2022, it secured USD 35 million in a Series A funding round led by Samsung Ventures, with Cardumen Capital, Varana Capital, OurCrowd, XT Hi-Tech, and others as participants. The funding was used to launch its flagship AI inferencing solution.
 
</div>

NeuReality

<div>
 
 Accubits is an AI and BLOCKCHAIN focused development and solutions company based in Washington DC with its development offices in India and Dubai. Pioneering as a custom Blockchain solutions provider delivering solutions ever since 2012, Accubits is one of the oldest and experienced Blockchain dev house in the market and is featured as one among the top 13 Blockchain companies in India by INC42. We are a big family of engineers, innovators, inventors and many others continually working to help our customers in leveraging their business and adding value to their lives. Over the past 6 years, We have delivered more than 600 projects, for over 200 clients worldwide. Several of Fortune 500 companies in sectors from Retail to Health are being powered by our solutions to streamline and leverage their growth.Our portfolio for AI solutions includes intelligent conversational tools, RPAs, CRMs, SIPs, real-time video and image analytics systems, state of the art ALPR systems and many more being used enterprises, startups across North America, Canada, Middle East, Hong Kong, Singapore, Indonesia, India &amp; Sweden. Our portfolio of Blockchain development includes custom DApps and smart contracts, crypto token and exchange development, integrated blockchain services and ICO platforms.
 
</div>

Accubits

<div>
 
 LeewayHertz is a leading software development company delivering tailor-made digital solutions to businesses worldwide. Our team of 250+ full-stack developers, designers and innovators has designed and developed 100+ digital solutions across industry verticals. As a close-knit team of AI and web3 experts, designers and full-stack developers, we undertake collaborative research and development to create next-gen applications and solutions perfectly suited to the evolving tech space. As a technology pioneer with deep knowledge and expertise in AI, blockchain and other advanced technologies like IoT, LeewayHertz believes in helping companies overcome their most complex tech challenges and drive business growth. Our motto, &lsquo;You Dream It: We Build It,&rsquo; reflects our business philosophy. From putting flesh on your idea to delivering the expected end product, we do whatever it takes to make your project successful. Having worked with 30+ top fortune 500 companies and created various on-demand solutions, we boast an impressive work portfolio demonstrating our expertise.
 
</div>

LeewayHertz

Databricks, a data and AI company established by the original developers behind prominent Big Data solutions such as Delta Lake, Apache Spark, and MLflow, and provides organizations with AI and data analytics tools for efficient management of their data.Databricks' primary product is the Databricks Lakehouse platform, a unified data intelligence platform that merges a data warehouse and data lake to provide developers with efficient access to data and enables enterprise customers to create their AI models—similar to a ChatGPT-style AI system—using only their internal data.Databricks Unity Catalog, part of the Databricks Lakehouse Platform, provides unified governance for structured and unstructured data, machine-learning models, notebooks, dashboards, and files across various environments, offering automated monitoring, proactive alerts, and seamless data sharing through Delta Sharing integration. Furthermore, Databricks offers an open architecture that streamlines the AI development process, allowing the integration of various LLMs such as Llama 2, Azure OpenAI, and Anthropic, enabling customization with enterprise data for tailored model creation.Notably, Lakehouse leverages NVIDIA technology for accelerated data processing and AI model generation. Databricks also offers industry-specific solutions like Databricks Lakehouse for Healthcare, Financial Services, Retail, and Manufacturing.Databricks has expanded its offerings through multiple acquisitions, including MosaicML ( <a href="https://sp-edge.com/updates/19683">July 2023 </a>), Arcion ( <a href="https://sp-edge.com/updates/23041">October 2023 </a>), Okera ( <a href="https://sp-edge.com/updates/18197">May 2023 </a>), and Datajoy (October 2022). Key customers and partnershipsAs of July 2023, Databricks served a global customer base of approximately 10,000, including notable customers such as Comcast, DuPont, Honeywell, Rolls-Royce, Shell, and Tata Steel.Notable partnerships include collaboration with NVIDIA to incorporate NVIDIA TensorRT-LLM into its inference service and a partnership with Hevo-Data to automate data integration into the lakehouse for mutual customers (October 2022).Databricks also partnered with Karini AI to accelerate GenAI deployment for enterprises (<a href="https://sp-edge.com/updates/33687">September 2024</a>)Databricks also provides an LLM Mesh partner program; it has partnered with firms such as <a href="https://sp-edge.com/updates/24218">Dataiku </a>where an emphasis is placed on comprehensive data access, enabling tight integration of GenAI applications with enterprise data.

Databricks

<div>
 
 Labelbox offers a data-centric AI platform for enterprises, enabling them to develop, optimize, and use AI to solve complex problems and power new products and services.&nbsp;&nbsp;
 
 
 Labelbox&rsquo;s platform offers capabilities for building, optimizing, training, fine-tuning LLMs, and AI-enabled data labeling automation.&nbsp;
 
 
 Its products include&nbsp;
 
 
 1) Catalog: A platform for building AI applications with features such as advanced search capabilities and optimizing data for labeling budgets
 
 
 2) Annotate: A data labeling solution designed to streamline and accelerate labeling operations using automation tools and pre-labeling techniques
 
 
 (3) Model: Offers tools for data enrichment, model-assisted labeling, and custom Foundry Apps to automate data management tasks and improve AI model performance&nbsp;&nbsp;
 
 
 (4) Boost: Offers fully managed tailored solutions such as on-demand data labeling services to enhance AI development speed and efficiency.&nbsp;
 
 
 As such, Labelbox enables companies to streamline the fine-tuning and alignment of LLMs and enables the validation of outputs through techniques such as reinforcement learning with human feedback (RLHF), reinforcement learning from AI feedback (RELIEF), and evaluation. This incorporation of human expertise ensures more accurate, contextually relevant, trustworthy, and secure results from LLM systems.
 
 
 The platform is offered through a SaaS subscription model with packages ranging from free subscriptions with limited usage and custom pricing for enterprises.
 
 
 Key customers and partnerships
 
 
 The firm's solutions have use cases across diverse industries, including retail, consumer internet, healthcare, manufacturing, and financial services. Labelbox has a large portfolio of customers, including NASA's Jet Propulsion Laboratory and Blue River Technology, a smart AgriTech company that used Labelbox's model-assisted labeling suite to enhance its See &amp; Spray technology in smart agriculture, resulting in herbicide cost savings of 70%&ndash;80. Labelbox's customers also include several Fortune 500 companies, such as Walmart, P&amp;G, Audi Adobe, Airbnb, Bayer, and Bosch.
 
 
 Key partnerships include a long-term collaboration with 
 <a href="https://sp-edge.com/updates/21770">
 Google Cloud
 </a>
 to facilitate digital transformations in retail, consumer internet, financial services, and manufacturing and logistics.
 
 
 Funding and financials
 
 
 In January 2022, the firm raised USD 110 million in Series D funding led by SoftBank's Vision Fund 2. The company planned to utilize the funds to finance company expansion.
 
 
 
</div>

Labelbox

Integrated solutions that handle various processes such as model training, fine-tuning, model deployment, monitoring, and maintenance in working with and deploying LLMs

Platforms that provide hardware such as high-performance CPUs, GPUs, or TPUs, including cloud-based solutions that are commonly used to train and run GenAI models efficiently

Platforms that assist with fine-tuning pre-trained GenAI models or custom models tailored to specific use cases. Includes services that train models from scratch or use existing models

Platforms that store and retrieve training data in vector databases for access during the model training phase

Services to deploy GenAI models (on-premises or cloud-based) into production environments and integration tools to support existing systems and workflows

Ongoing monitoring of GenAI models to ensure performance. Includes regular model retraining, performance optimization, and troubleshooting

Platforms that assist in designing and refining prompts or instructions to GenAI models to get the desired responses or outcomes

Platforms that enable safe, responsible, and ethical GenAI deployment, ensuring compliance with regulations and/or protection against GenAI-based cybersecurity threats.

All services offered by these companies provide support to AI/ML

NLP is a key component of generative AI which is the core focus of this hub.

All companies within this space are offering infrastructure for generative AI

Generative AI infrastructure hub covers companies that deploy and run these foundation models.

Daiki is an AI governance and compliance solutions provider that offers a SaaS platform, which integrates document and quality management systems (eQMS) with streamlined processes for AI development. It helps organizations comply with the EU AI Act and ISO standards, including ISO 13485 for medical device manufacturers.&nbsp;Its product includes an AI Copilot feature to support AI implementation at scale.&nbsp;Key customers and partnershipsAs of November 2024, the company served the medical technology, healthcare, and manufacturing sectors, focusing on the DACH region (Germany, Austria, and Switzerland), the UK, Netherlands, and Scandinavia. Its technology partners included Azure, Google Cloud, Snowflake, Databricks, and Jira.&nbsp;

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

ANALYST_QUICK_TAKE

<div>
 DAIKI GmbH, an AI governance platform, has successfully secured seed funding of EUR 1.5 million (~USD 1.6 million). The capital comes from Humanitas GmbH, a firm established by Tarek Sherif who is also a co-founder of Medidata Solutions and currently chairs the Life Sciences Sector Board at Dassault Systèmes.
 By utilizing the funding, DAIKI anticipates expediting its developmental endeavors, which also encompasses the creation of a new AI model registry feature. Besides, the company plans on expanding its team and intensifying its market influence throughout Europe.
 Functioning mostly in the MedTech, healthcare, and manufacturing sectors within the DACH region, the United Kingdom, the Netherlands, and Scandinavia, DAIKI delivers SaaS solutions for AI governance. They ensure compliance with the EU AI Act and ISO standards. University Hospital Basel and Seco Tools are among their notable clientele. 
</div> Analyst QuickTake: 
 The enforcement of the EU AI Act from <a href="https: 
//sp-edge.com/updates/32259"> August 2024 </a> has accelerated the need for GenAI-based enterprises in Europe to comply with the new regulations. Other recent AI governance platforms that raised funding included <a href="https: 
//sp-edge.com/updates/32747"> ModelOp </a> (USD 10 million) and <a href="https: 
//sp-edge.com/updates/33301"> Acuvity </a> (USD 9 million).

DAIKI

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless